ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Alterola Biotech Inc (PK)

Alterola Biotech Inc (PK) (ABTI)

0.003
0.00
(0.00%)
Closed 22 December 8:00AM

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
0.003
Bid
0.003
Offer
0.0076
Volume
-
0.00 Day's Range 0.00
0.0023 52 Week Range 0.022
Market Cap
Previous Close
0.003
Open
-
Last Trade
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
15,536
Shares Outstanding
1,459,502,018
Dividend Yield
-
PE Ratio
0.00
Earnings Per Share (EPS)
-0
Revenue
-
Net Profit
-2.37M

About Alterola Biotech Inc (PK)

ALTEROLA BIOTECH INC. (OTC QB: ABTI) is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary product platform in a broad range of disease areas. The Company has a number of proprietary drug pipeline candidates including cannabinoi... ALTEROLA BIOTECH INC. (OTC QB: ABTI) is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary product platform in a broad range of disease areas. The Company has a number of proprietary drug pipeline candidates including cannabinoids, cannabinoid-like molecules and non-cannabinoid molecules, which are under development for a range of indications. ABTI is also focused on producing quality, low cost of goods ingredients for the pharmaceutical, food and cosmetic sectors, from synthetic, biosynthetic and botanical sources. It is also focused on improving the drug delivery of such classes of compounds and has a range of proprietary technologies in development to enhance the delivery and bioavailability of its product portfolio. Geographically the Company has a presence in the UK, Ireland, Netherlands (Europe), USA, Australia, and China. Show more

Sector
Medicinal Chems,botanicl Pds
Industry
Medicinal Chems,botanicl Pds
Headquarters
Las Vegas, Nevada, USA
Founded
-
Alterola Biotech Inc (PK) is listed in the Medicinal Chems,botanicl Pds sector of the OTCMarkets with ticker ABTI. The last closing price for Alterola Biotech (PK) was US$0. Over the last year, Alterola Biotech (PK) shares have traded in a share price range of US$ 0.0023 to US$ 0.022.

Alterola Biotech (PK) currently has 1,459,502,018 shares in issue. The market capitalisation of Alterola Biotech (PK) is US$4.38 million. Alterola Biotech (PK) has a price to earnings ratio (PE ratio) of 0.00.

ABTI Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1000.0030.0030.00392000.003CS
4-0.002-400.0050.00770.00372360.00627312CS
12-0.001-250.0040.0090.003155360.00545838CS
26-0.01325-81.53846153850.016250.0220.003352250.01357927CS
520.000415.38461538460.00260.0220.0023285190.01124215CS
156-0.22-98.65470852020.2230.270.0012628420.03199595CS
260-0.897-99.66666666670.93.090.0012445540.06652778CS

ABTI - Frequently Asked Questions (FAQ)

What is the current Alterola Biotech (PK) share price?
The current share price of Alterola Biotech (PK) is US$ 0.003
How many Alterola Biotech (PK) shares are in issue?
Alterola Biotech (PK) has 1,459,502,018 shares in issue
What is the market cap of Alterola Biotech (PK)?
The market capitalisation of Alterola Biotech (PK) is USD 4.38M
What is the 1 year trading range for Alterola Biotech (PK) share price?
Alterola Biotech (PK) has traded in the range of US$ 0.0023 to US$ 0.022 during the past year
What is the reporting currency for Alterola Biotech (PK)?
Alterola Biotech (PK) reports financial results in USD
What is the latest annual profit for Alterola Biotech (PK)?
The latest annual profit of Alterola Biotech (PK) is USD -2.37M
What is the registered address of Alterola Biotech (PK)?
The registered address for Alterola Biotech (PK) is 4955 S. DURANGO DR STE, 165, LAS VEGAS, NV, 89113, USA, LAS VEGAS, NEVADA, 89113
What is the Alterola Biotech (PK) website address?
The website address for Alterola Biotech (PK) is www.alterolabio.com
Which industry sector does Alterola Biotech (PK) operate in?
Alterola Biotech (PK) operates in the MEDICINAL CHEMS,BOTANICL PDS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
ELIQQElectriq Power Holdings Inc (CE)
US$ 0.10
(99,900.00%)
100
GNTLFGenetic Technologies Ltd (PK)
US$ 1.00
(90,809.09%)
100
VIVEViveve Medical Inc (CE)
US$ 0.0003
(29,900.00%)
7.33k
BTIMBoatim Inc (CE)
US$ 0.0002
(19,900.00%)
799
CLVRClever Leaves Holdings Inc (CE)
US$ 0.0002
(19,900.00%)
592
RAASYCloopen Group Holding Limited (CE)
US$ 0.000001
(-100.00%)
214
EWGFFEat Well Investment Group Inc (CE)
US$ 0.000001
(-100.00%)
47.01k
SOLBFSoLVBL Solutions Inc (CE)
US$ 0.000001
(-99.99%)
10k
HAVLFHavn Life Sciences Inc (CE)
US$ 0.000001
(-99.98%)
4.02k
ENDRFEndor AG (GM)
US$ 0.0001
(-99.98%)
560
HMBLHUMBL Inc (PK)
US$ 0.00095
(5.56%)
344.89M
PHILPHI Group Inc (PK)
US$ 0.0003
(0.00%)
312.21M
PLPLPlandai Biotechnology Inc (PK)
US$ 0.0001
(0.00%)
215.71M
RDARRaadr Inc (PK)
US$ 0.0014
(16.67%)
174.96M
CHNVFChina Youzan Ltd (PK)
US$ 0.0177
(10.63%)
100M

ABTI Discussion

View Posts
Captk Captk 9 months ago
Any updates out there?
πŸ‘οΈ0
Captk Captk 9 months ago
Any updates out there?
πŸ‘οΈ0
DawgTrading DawgTrading 2 years ago
ABTI so these are actually 0.06 per share per the BGXX call option.

When is this transaction taking place?
πŸ‘οΈ0
DawgTrading DawgTrading 2 years ago
ABTI this one being bought out?

Seems BGXX is giving shares for consideration... ABTI is becoming BGXX?

Whats the ratio how many shares of BGXX for each share of ABTI?

Any info is welcome.
πŸ‘οΈ0
samsamsamiam samsamsamiam 3 years ago
SEC Charges Multiple Defendants with Investment Fraud Scheme Involving Penny Stock Companies

Litigation Release No. 25414 / June 9, 2022

Securities and Exchange Commission v. Trends Investments Inc. et al., Civil Action No. 1:22-cv-10889 (D. Mass. filed June 8, 2022)

The Securities and Exchange Commission charged one company and five individuals in connection with a securities fraud scheme involving the offer and sale of stock in two publicly traded penny stock companies.

According to the SEC's complaint, Trends Investments Inc., an unregistered entity, and Trends personnel Clinton Greyling of Florida, Leslie Greyling (Clinton's father, a resident of the United Kingdom), and former Massachusetts resident Brandon Rossetti engaged in a scheme to defraud investors in private offers and sales of shares of two publicly traded penny stock companies, Alterola Biotech Inc. and Token Communities Ltd. The Greylings and Rossetti allegedly lied to investors about whether Trends owned and could deliver to investors the shares it claimed to be selling. They are further charged with making a variety of misrepresentations to investors in order to keep investor funds, obtain further investments, placate investor concerns, and avoid detection. According to the complaint, Rossetti also acted as an unregistered broker by soliciting investors, receiving transaction-based compensation from Trends, and claiming to be a "broker" or "wealth manager."

The SEC's complaint also charges New York resident Roger Bendelac with participating in the scheme by placing manipulative trades in one of the securities Trends was offering and selling to investors, including through the use of two relatives' brokerage accounts to purchase securities which Bendelac sold from a different brokerage account. The SEC's complaint also alleges that Bendelac's relative, New York resident Thomas Capellini, gave Bendelac access to Capellini's brokerage account and funded the account so that Bendelac could place manipulative trades.

The SEC's complaint, filed in federal court in Boston, Massachusetts, charges Trends, Clinton Greyling, Leslie Greyling, and Rossetti with violating Section 17(a) of the Securities Act of 1933 ("Securities Act") and Section 10(b) of the Securities Exchange Act of 1934 ("Exchange Act") and Rule 10b-5 thereunder. The complaint also charges Rossetti with violating Section 15(a) of the Exchange Act, charges Bendelac with violating Sections 17(a)(1) and (3) of the Securities Act and Sections 9(a)(2) and 10(b) of the Exchange Act and Rules 10b-5(a) and (c) thereunder, as well as aiding and abetting Trends', Rossetti's, and the Greylings' violations, and charges Capellini with aiding and abetting Bendelac's violations. The SEC's complaint seeks remedies that include injunctions, disgorgement, prejudgment interest, civil penalties, and penny stock bars. Without admitting or denying the allegations, Clinton Greyling has consented to the entry of a judgment permanently enjoining him from future violations of the charged provisions. In addition, Clinton Greyling has consented to a penny stock bar. The settlement, which is subject to court approval, would leave disgorgement, prejudgment interest, and civil penalties to be determined by the court at a later date.

The SEC's case is being handled by by J. Lauchlan Wash, Trevor Donelan, David M. Scheffler, and Amy Gwiazda of the SEC's Boston Regional Office. The SEC appreciates the assistance of the Financial Industry Regulatory Authority (FINRA), the Colorado Division of Securities, and the Florida Office of Financial Regulation.

https://www.sec.gov/litigation/litreleases/2022/lr25414.htm
Complaint
https://www.sec.gov/litigation/complaints/2022/comp25414.pdf
πŸ‘οΈ0
tarpon21 tarpon21 3 years ago
Been soaking. Oversold and a lot in the pipeline. Was reading last night they announced earlier in the year they plan to uplist? That said, can’t ignore the PPS is down like 50% over past two weeks. They really need to get a Twitter account and attract new investors like CYBL and others do. Still, I really like their management team and the current price is comical. I’m long and strong.

Anyone else have some DD?
πŸ‘οΈ0
Thugmuffin Thugmuffin 3 years ago
$ABTI Alterola Biotech, Inc. Featured in the PharmaInvestor MagazinePress Release | 04/20/2022

CannaInvestor Magazine Launches New Magazine - PharmaInvestor Magazine

ATLANTA, GA / ACCESSWIRE / April 20, 2022 / Alterola Biotech, Inc. (OTC PINK:ABTI) a UK based pharmaceutical company will be the featured company in the new PharmaInvestor Magazine May 2022 Issue. Despite the downturn in Cannabis, Hemp, and CBD investment sectors, the demand for Cannabis pharmaceutical and biotech investments has prompted Cannabis Investor Magazine and HempCBD Investor Magazine to launch a new title - PharmaInvestor Magazine, to cater to this growing cannabinoid medicine market. The PharmaInvestor Magazine goal is to become the leading industry investment magazine for cannabinoid pharmaceutical and biotech investors, analysts, executives, entrepreneurs, and the financial media. Content will focus on companies developing cannabis-based, cannabinoid and cannabinoid-like prescription medicines, their research pipelines, and intellectual property portfolios. The digital version of the magazine will be accessible and free for the first year to all subscribers who enter their email address. The Alterola Biotech Inc. feature can be found by visiting our website (www.cannainvestormag.com) in the first half of May 2022.

To date, investing in the cannabinoid pharmaceutical and biotech sector has been overshadowed by the recreational sector, but with the success of GW Pharmaceuticals (JAZZ), pharmaceutical companies like Pfizer (PFE) expanding their cannabinoid portfolios, cannabinoid pharmaceutical companies such as Cardiol Therapeutics Inc. listing on NASDAQ, and investments starting to rise in this sector, Cannabis investor interest from outside the space is increasingly growing. The new PharmaInvestor Magazine will feature industry companies, insights, and interviews with key players to help investors uncover the hidden gems in this fast-moving sector.

The cannabinoid pharmaceutical and biotech sectors have everything investors could ask for in terms of sophisticated approaches, strong teams, clear business models, and first mover advantages. It has been the preserve of some very early adopters so far, and our intention is to open this sector up to a wider investor base. With 120,000 subscribers for our current magazines, the new PharmaInvestor Magazine will build on CannaInvestor Magazine's existing audience reach.

Tim Rogers, Executive Chairman states, "Over the past year we have reached major milestones and made significant progress in the development of the Company. PharmaInvestor Magazine will assist us in increasing our exposure to its investor audience, so they can perform their due diligence, understand the sector clearly, make an informed investment decision, and invest in Alterola with confidence, should they wish. It's difficult for those who do not know our sector well to be aware of new and emerging innovative companies. The PharmaInvestor Magazine is an opportunity to educate investors and give them early access to Alterola and other great companies."

Seamus McAuley, CEO states, "We're excited to be the first featured company in the PharmaInvestor Magazine. Alterola aims to bring next generation cannabinoid and cannabinoid-like pharmaceutical medicines to the market in the form of life changing medicines. Our diversified portfolio of product development candidates and technologies will potentially allow us to generate multiple revenue streams, which should, if successful, significantly impact top-line growth."

About Alterola Biotech, Inc.

Alterola Biotech, Inc. is a UK based pharmaceutical company developing cannabinoid, cannabinoid-like, and non-cannabinoid pharmaceutical active pharmaceutical ingredients (APIs) and targeting European novel food approval of cannabinoid-based, cannabinoid-like and non-cannabinoid ingredients and products. If you would like more information about Alterola Biotech Inc., please visit our website https://alterola-abti.com/ or contact our Investor Relations Department at +353 86 838 9812 or ir@alterolabio.com.

CannaInvestor Magazine

CannaInvestor Magazine is a free monthly subscription based digital magazine with an exclusive focus on Cannabis industry finance that delivers convenient insights on publicly-traded and privately-held cannabis companies through informative articles, company profiles, and market trends that inform and educate cannabis investors, analysts, executives, entrepreneurs, and the financial media. For more information, please visit our websites www.cannainvestormag.comwww.cannainvestorcanada.com.

Cannabis Investor Magazine

1 (888) 575-1254, Ext. 1
team@cannainvestormag.com
www.cannainvestormag.com
πŸ‘οΈ0
Captk Captk 3 years ago
Good afternoon

Any updates out there?

Have a great day
πŸ‘οΈ0
@AurumStock @AurumStock 3 years ago
A couple of press releases out the past few weeks.
Things seem to happening
πŸ‘οΈ0
Planter Planter 3 years ago
Response to traffic on Alterola, I went and found out the truth for personal reasons. Why the SP fall. Long term shareholder in EU was conned out of 500,000 free trading shares, he wasn't paid, he made a mistake. Company and people that did this laid a false trail but are well known for this (see MMG injunction). Stock was dumped and management stopped releases and launch just in time given uncertainty. These Florida guys made less than $60k selling shares they stole. Don't worry about this company, it is solid and has backing and will soon announce their program now they have shares under control. It is a buy at anything under $1 IMO. Check out mgmt team, even more impressive when you meet them, if you think these guys are going to lose then think again. I called them, they replied and were open without being accusatory, very professional and very confident.
πŸ‘οΈ0
Beryl J Beryl J 3 years ago
See the press release as to the promoter and then search for a defamation lawsuit filed in Canada and voided in the US, you will see that, by policy, it appears to be forbidden for posters to mention that person's name and company on InvestorsHub - even though now involved in ABTI / EMC2 Capital
πŸ‘οΈ0
Beryl J Beryl J 3 years ago
Read Form 10-KT, June 9, 2021 and Form S-1, October 19, 2021: "During the period ended March 31, 2021, Bulls Run Limited (Leslie Greyling) made advances to the company to fund operating expenses in the amount of $50,000. These advances are non – interest bearing and have no specified terms of repayment." Then look up "Leslie Greyling".
πŸ‘οΈ0
@AurumStock @AurumStock 3 years ago
Had a huge market cap.
With the S1 it seems to small now
πŸ‘οΈ0
TDV3rd TDV3rd 3 years ago
What is happening with this company O.o
πŸ‘οΈ0
Doflamingo Doflamingo 3 years ago
Hoping for the best, expecting the worst!
πŸ‘οΈ0
Doflamingo Doflamingo 3 years ago
Keeping us in dark, nothing makes sense. Looks like they are ignoring the real reason for the decline of PPS, for some reason.
πŸ‘οΈ0
TDV3rd TDV3rd 3 years ago
What is happening here... This is going from bad to worse very very fast!
πŸ‘οΈ0
TDV3rd TDV3rd 3 years ago
Well, this is in a deep deep s***
πŸ‘οΈ0
TDV3rd TDV3rd 3 years ago
If somebody told me a couple of days ago that $ABTI is gonna sink so fast I would never even look at it.

This is a disaster.
πŸ‘οΈ0
TDV3rd TDV3rd 3 years ago
How can somebody write so many bulls*** in one PR???

It "We didn't do this somebody did", "We didn't write that somebody did"...

Do these people even know what is happening in this company???


πŸ‘οΈ0
TDV3rd TDV3rd 3 years ago
Wait what O.o

https://finance.yahoo.com/news/alterola-biotech-inc-issues-statement-211500811.html
πŸ‘οΈ0
Original Bad Bob Original Bad Bob 3 years ago
Now that we have a press release from ABTI, its more confusing than ever. Evidently someone (or persons) have been circulating misinformation resulting in the stock to crash? But there is no mention of who the party is, what was said, or why. Jeez.
πŸ‘οΈ0
Captk Captk 3 years ago
https://finance.yahoo.com/news/alterola-biotech-inc-issues-statement-211500811.html
πŸ‘οΈ0
Doflamingo Doflamingo 3 years ago
Shareholders will abandon this co if we don't hear from them soon. Unfortunately, pps will only plummet until they issue a press release!
πŸ‘οΈ0
Doflamingo Doflamingo 3 years ago
Not looking good at all. Management needs to issue a press release ASAP
πŸ‘οΈ0
Original Bad Bob Original Bad Bob 3 years ago
Never mind the technicalities of day trading. What, if anything, caused the stock to plummet 72% yesterday and another 50% today?

If all anyone has to say is profit taking, then this so-called company is not worth following.

So does anyone know what happened?
πŸ‘οΈ0
Captk Captk 3 years ago
Good afternoon

The only good news is someone actually bought roughly 250k shares so even at a 20 cents average - $50k was invested today that's more than in the last several months. There was definitely a seller - kept almost 40,000 shares on the bid all day long.

tomorrow is another day - any thoughts on a entry point ? for a bounce
πŸ‘οΈ0
Baron123 Baron123 3 years ago
What's going on??? I hoped the stock price will recover, they are going deeper and deeper, the PPS is sinking, can anyone explain what is happening here?
πŸ‘οΈ0
Baron123 Baron123 3 years ago
I agree, hope to see some fresh updates soon!

$ABTI
πŸ‘οΈ0
TDV3rd TDV3rd 3 years ago
It's a little red but that's gonna change.

Management will put $ABTI on a right track.
πŸ‘οΈ0
Baron123 Baron123 3 years ago
Looks promising indeed, thanks for sharing! $ABTI
πŸ‘οΈ0
TDV3rd TDV3rd 3 years ago
Day by day $ABTI is gonna get better and better.

In a long term, it's gonna be worth waiting.
πŸ‘οΈ0
TDV3rd TDV3rd 3 years ago
And I just got the press release for $ABTI.

This looks very very PROMISING!!!

https://www.einpresswire.com/shareable-preview/C7ZoGHaPQFrCsgZi7nrl6A
πŸ‘οΈ0
Baron123 Baron123 3 years ago
I agree, this looks promising! A lot of potentials here, which I am certainly going to keep a close eye on it.
πŸ‘οΈ0
TDV3rd TDV3rd 3 years ago
A friend of mine recommended $ABTI to me the other day. Based on small research I can say this is better than I expected.

πŸ‘οΈ0
Beryl J Beryl J 3 years ago
Source of funding at ABTI? Per Form 10-KT, June 9, 2021: "During the period ended March 31, 2021, Bulls Run Limited (Leslie Greyling) made advances to the company to fund operating expenses in the amount of $50,000. These advances are non – interest bearing and have no specified terms of repayment."
πŸ‘οΈ0
zerohedge zerohedge 4 years ago
give it time. there's a lot being filed from what it looks like.
πŸ‘οΈ0
Golden Cross Golden Cross 4 years ago
ABTI Pink Current
https://www.otcmarkets.com/stock/ABTI/disclosure
πŸ‘οΈ0
Beryl J Beryl J 4 years ago
Dheeraj Jain, Lalit Kumar Verma, Alex Lightman, Irving Aronson and Peter Maddocks out at ABTI? They all out at Token too?
πŸ‘οΈ0
@AurumStock @AurumStock 4 years ago
https://www.otcmarkets.com/filing/html?id=14803546&guid=3MRpU6y4Z0FWyth

πŸ‘οΈ0
zerohedge zerohedge 4 years ago
what do you know?

πŸ‘οΈ0
resx18 resx18 4 years ago
$ABTI 10-Q https://www.otcmarkets.com/filing/html?id=14432429&guid=v-K6UKDt7okLeth
πŸ‘οΈ0
resx18 resx18 4 years ago
Off to do DD
πŸ‘οΈ0
resx18 resx18 4 years ago
looking at SS
πŸ‘οΈ0
resx18 resx18 4 years ago
Looks like we have a nice one here
πŸ‘οΈ0
resx18 resx18 4 years ago
hi
πŸ‘οΈ0
Renee Renee 5 years ago
ALTA changed to ABTI:

https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes
πŸ‘οΈ0
Awl416 Awl416 5 years ago
Lol That isn’t buying. You cant trade this volume
πŸ‘οΈ0
buxmaker buxmaker 5 years ago
Buying continues in ALTA. $1.45.
πŸ‘οΈ0
buxmaker buxmaker 5 years ago
Another up today for ALTA. Someone keeps stepping in and buying.
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock